1. Home
  2. LKFN vs CGEM Comparison

LKFN vs CGEM Comparison

Compare LKFN & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lakeland Financial Corporation

LKFN

Lakeland Financial Corporation

HOLD

Current Price

$60.58

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$20.59

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LKFN
CGEM
Founded
1872
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
2009
2020

Fundamental Metrics

Financial Performance
Metric
LKFN
CGEM
Price
$60.58
$20.59
Analyst Decision
Hold
Strong Buy
Analyst Count
3
8
Target Price
$67.00
$30.13
AVG Volume (30 Days)
124.1K
722.5K
Earning Date
04-27-2026
05-11-2026
Dividend Yield
3.49%
N/A
EPS Growth
10.47
N/A
EPS
2.17
N/A
Revenue
$985,000.00
N/A
Revenue This Year
$15.50
N/A
Revenue Next Year
$5.51
$5.20
P/E Ratio
$27.75
N/A
Revenue Growth
N/A
N/A
52 Week Low
$54.36
$5.68
52 Week High
$66.82
$23.19

Technical Indicators

Market Signals
Indicator
LKFN
CGEM
Relative Strength Index (RSI) 47.44 52.22
Support Level $60.19 $11.87
Resistance Level $61.17 $23.19
Average True Range (ATR) 1.00 0.87
MACD 0.09 -0.25
Stochastic Oscillator 62.11 21.52

Price Performance

Historical Comparison
LKFN
CGEM

About LKFN Lakeland Financial Corporation

Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare. The company's revenue is derived from the business of banking.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: